DBV Technologies to Present at the LEERINK Partners 5th Annual Global Healthcare Conference


A live audio webcast of the presentation will be available on the Investor Relations section of the Company’s website, http://www.dbv-technologies.com/en/investor-relations. A replay will also be available 48 hours after the event.

About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies – a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation and Breakthrough Therapy designation from the U.S. Food and Drug Administration.

DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

DBV Technologies Contacts

Nathalie Donne
Director, Corporate Communication & Business Development
Tel.: +33 (0)1 55 42 78 72
nathalie.donne@dbv-technologies.com

Susanna Mesa
VP of Finance, Investor Relations & Strategy
Tel.: +1 212-271-0861
susanna.mesa@dbv-technologies.com

DBV Technologies Media Contacts US & Europe

Marion Janic
Rooney & Associates
Tel.: +1 212-223-4017
mjanic@rooneyco.com

Caroline Carmagnol
Alize RP – Relation Presse
Tel.: +33 (0)6 64 18 99 59
caroline@alizerp.com